Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0005940 (
bone disease
)
7,459
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Bone disease
is a major cause of morbidity in end stage renal failure. This study is aimed to assess the prevalence of abnormal bone mineral density (BMD), measured by dual photon absorptiometry (DPA) in the renal transplant population. Subjects consisted of 110 patients followed up after transplantation for between 1 and 17 years. Variables analyzed included age, sex, ethic origin, years and type of dialysis prior to transplantation, date of transplant, total steroid dose, number of rejection episodes, use of Cyclosporin, and biochemical/hormonal variables such as serum calcium, phosphate, magnesium, alkaline phosphatase, creatinine,
FSH
, LH and PTH. Analysis of variance and chi square tests were performed to assess the differences between groups and Pearson correlation coefficients were obtained. The total steroid dose, year of birth, PTH level and duration since transplantation were correlated with BMD (p < 0.05). Despite the statistical significance, the degree of variability indicated by each of these variables was low revealed by multiple regression analysis. We conclude that although steroid therapy is a major contributor to the increase in osteoporosis in renal transplant patients, about two thirds of the parameters that can influence bone metabolism remain unexplained.
...
PMID:Factors affecting bone mineral density in renal transplant patients. 1043 73
In the last years, new evidences of the relationship between immune system and bone have been accumulated both in animal models and in humans affected by
bone disease
, such as rheumatoid arthritis, bone metastasis, periodontitis, and osteoporosis. Osteoporosis is characterized by low bone mass and microarchitectural deterioration of bone tissue with a subsequent increase in bone fragility and susceptibility to fractures. The combined effects of estrogen deprivation and raising of
FSH
production occurring in menopause cause a marked stimulation of bone resorption and a rapid bone loss which is central for the onset of postmenopausal osteoporosis. This review focuses on the role of immune system in postmenopausal osteoporosis and on therapeutic strategies targeting osteoimmunology pathways.
...
PMID:Postmenopausal osteoporosis: the role of immune system cells. 2376 93
Background
. Aromatase inhibitors (AIs) are used for adjuvant therapy of breast cancer; however AIMSS (AI-Associated Musculoskeletal Symptoms) can negatively affect quality of life and compliance. Most patients in China moved to TCM (traditional Chinese medicine) for help. TB (tiger bone) is used to treat
bone disease
, whose main ingredients are calcium and collagen. The objective of this study was to evaluate whether the TB prevented AIMSS in postmenopausal women with ER/PR+ breast cancer.
Methods
. We conducted a randomized, blind, controlled study of comparing TB versus placebo for 12 weeks in postmenopausal women with breast cancer who have taken AI for less than a month. Patients completed the M-BPI, VAS, and FACT-B at baseline, 6 weeks, and 12 weeks. M-BPI and VAS were used as the primary outcomes. FACT-B was used as the secondary outcome. Serum E
2
and
FSH
were tested every 6 weeks.
Results
. Of 70 evaluable cases, 8 of 35 patients (22.9%) developed new or worsening point symptoms in TB group, compared to 21 of 35 (60%) in placebo group (
P
< 0.001). We also found differences between 2 groups in average pain (2 to 5.6), worst pain (3.9 to 8), pain interference severity (1.9 to 5.3), stiffness (2.4 to 6.9), and joint symptom interference (1.8 to 5.7), all
P
< 0.001; similar findings were seen in VAS value (3 to 6.6) at the end of intervention. HRQoL measured by FACT-B (
P
< 0.05) was improved. No change of serum estradiol and
FSH
between two groups.
Conclusions
. TB appeared to be effective and safe in the prevention of AIMSS. This trial is registered with ChiCTR-IPR-15007081.
...
PMID:Traditional Chinese Medicine Bionic Tiger Bone Powder for the Treatment of AI-Associated Musculoskeletal Symptoms. 2825 Jul 92